Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training
This study has been completed.
Sponsor:
German Cancer Research Center
Collaborator:
University of Heidelberg
Information provided by:
German Cancer Research Center
ClinicalTrials.gov Identifier:
NCT00196885
First received: September 12, 2005
Last updated: June 18, 2008
Last verified: June 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to tests the hypothesis, that N-acetylcysteine (a thiol-antioxidant)improves the exercise training effect on cancer patients that experience weight loss (cachexia) as assessed by muscle mass and function as well as histomorphology.
Condition | Intervention | Phase |
---|---|---|
Gastrointestinal Neoplasms Bronchial Carcinoma Hodgkin Disease Non-Hodgkin Lymphoma Weight Loss |
Drug: N-acetylcysteine |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Official Title: | Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study) |
Resource links provided by NLM:
MedlinePlus related topics:
Antioxidants
Cancer
Exercise and Physical Fitness
Hodgkin Disease
Lymphoma
Weight Control
Drug Information available for:
Acetylcysteine
U.S. FDA Resources
Further study details as provided by German Cancer Research Center:
Primary Outcome Measures:
- muscle cross-sectional area, peak forces
Secondary Outcome Measures:
- muscle fiber composition (biopsy vastus lateralis muscle mRNA levels of cytokines, myostatin. Activity of Akt-dependent pathways
- muscle 31Phospho-magnetic-resonance spectroscopy
Estimated Enrollment: | 60 |
Study Start Date: | December 2003 |
Study Completion Date: | December 2006 |
Eligibility
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- gastrointestinal or bronchial cancer
- weight loss of 10% within 6 months
- sufficient mobility
Exclusion Criteria:
- severe pain, steroid therapy, severe internal, muscular, neurological, psychiatric disease, N-acetylcysteine allergy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00196885
Locations
Germany | |
German Cancer Research Center, D020 | |
Heidelberg, Baden-Württemberg, Germany, 69120 |
Sponsors and Collaborators
German Cancer Research Center
University of Heidelberg
Investigators
Study Director: | Wulf Hildebrandt, MD | German Cancer Research Center |
More Information
Publications:
Keywords provided by German Cancer Research Center:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
Publications:
ClinicalTrials.gov Identifier: | NCT00196885 History of Changes |
Other Study ID Numbers: | whilde157/2003 |
Study First Received: | September 12, 2005 |
Last Updated: | June 18, 2008 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by German Cancer Research Center:
cancer cachexia muscle wasting weight loss proteolysis |
Additional relevant MeSH terms:
Neoplasms Carcinoma Carcinoma, Bronchogenic Gastrointestinal Neoplasms Digestive System Neoplasms Hodgkin Disease Lymphoma Lymphoma, Non-Hodgkin Weight Loss Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Lung Diseases Respiratory Tract Diseases Digestive System Diseases Gastrointestinal Diseases Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Body Weight Changes Body Weight Signs and Symptoms Acetylcysteine N-monoacetylcystine Antiviral Agents |
ClinicalTrials.gov processed this record on October 16, 2012